Posts tagged drug enforcement agency

Demand the Senate Judiciary Committee Investigate DEA Abuse of Daniel Chong

Senate Judiciary Committee Chair Senator Patrick Leahy:

On April 21st, the Drug Enforcement Agency raided a 4/20 party at the University of California at San Diego, arresting 23-year-old Daniel Chong and others who had been smoking marijuana.

But after questioning Daniel, DEA agents abandoned him in a cell, handcuffed, without food and water for 5 days straight. Daniel was forced to drink his own urine and even attempted suicide.

The DEA’s reprehensible treatment of Daniel Chong almost cost him his life and deserves intense scrutiny.

We, the undersigned, demand the Senate Judiciary Committee investigate how Daniel could have been so abused by the DEA and hold accountable all those responsible.

Shortage of ADHD drug Adderall seen persisting


A shortage of Adderall, which is used to treat attention deficit hyperactivity disorder, shows little sign of easing as manufacturers struggle to get enough active ingredient to make the drug and demand climbs. Adderall, a stimulant, is a controlled substance, meaning it is addictive and has the potential to be abused. The Drug Enforcement Administration tightly regulates how much of the drug’s active pharmaceutical ingredient (API) can be distributed to manufacturers each year. The system is designed to prevent the creation of stockpiles that could be diverted for inappropriate use. Adderall and other stimulants are popular with students who may not have ADHD but are seeking to improve their test scores.

The DEA authorizes a certain amount of the API in Adderall - mixed amphetamine salts - to be released to drugmakers each year based on what the agency considers to be the country’s legitimate medical need. Increasingly that estimate is coming into conflict with what companies themselves say they need to meet demand for the drug, which is reaching all-time highs. In 2010, more than 18 million prescriptions were written for Adderall, up 13.4 percent from 2009, according to IMS Health, which tracks prescription data. Concerns are now rising among patient groups and doctors that the shortages seen in 2011 will continue into this year. Many orders remain unfilled, manufacturers say, and it may take several months before ingredient authorized under the new 2012 quota can be turned into new product.

so, um, how does the DEA decide what it considers to be the country’s legitimate medican need?

Drug enforcement before health care: if health care is not a right, it’s a sign of screwed up priorities.